OGEN
Oragenics, Inc.
Price Chart
Latest Quote
$0.57
-0.02 (-3.38%)
Current Price
| Previous Close | $0.59 |
| Open | $0.57 |
| Day High | $0.57 |
| Day Low | $0.57 |
| Volume | 11,102 |
Stock Information
| Shares Outstanding | 4.51M |
| Total Debt | $56K |
| Cash Equivalents | $6.11M |
| Net Income | $-9.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.56M |
| EPS (TTM) | $-4.95 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-3.44M |
| Income | $-9.83M |
| Book/sh | $1.41 |
| Cash/sh | $1.35 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 4.67 |
| Current Ratio | 5.73 |
| Debt/Eq | 0.91 |
Returns & Margins
| ROA | -105.56% |
| ROE | -311.00% |
Ownership
| Insider Ownership | 1.93% |
| Institutional Ownership | 5.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.05 |
| PEG | -8.96 |
| P/B | 0.40 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.60 |
| SMA50 | $0.61 |
| SMA200 | $0.87 |
| RSI | 38.53 |
| ATR | 0.0323 |
| Shares Float | 4.42M |
| Short Float | 15.73% |
| Short Ratio | 14.07 |
| Volatility | 1.26 |
| Rel Volume | 0.21 |
Performance History
| Week | -8.34% |
| Month | -3.68% |
| Quarter | -16.43% |
| 6 Months | -30.70% |
| YTD | -32.35% |
| Year | -84.43% |
| 3 Years | -99.37% |
| 5 Years | -99.96% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $0.57 | 11,102 |
| 2026-06-22 | $0.58 | 70,900 |
| 2026-06-18 | $0.55 | 94,000 |
| 2026-06-17 | $0.61 | 26,400 |
| 2026-06-16 | $0.61 | 50,800 |
| 2026-06-15 | $0.62 | 49,500 |
| 2026-06-12 | $0.62 | 28,100 |
| 2026-06-11 | $0.62 | 50,100 |
| 2026-06-10 | $0.59 | 44,100 |
| 2026-06-09 | $0.60 | 24,700 |
| 2026-06-08 | $0.60 | 24,700 |
| 2026-06-05 | $0.59 | 27,000 |
| 2026-06-04 | $0.60 | 29,000 |
| 2026-06-03 | $0.61 | 43,700 |
| 2026-06-02 | $0.61 | 70,300 |
| 2026-06-01 | $0.61 | 244,400 |
| 2026-05-29 | $0.61 | 26,200 |
| 2026-05-28 | $0.60 | 75,300 |
| 2026-05-27 | $0.59 | 35,100 |
| 2026-05-26 | $0.59 | 41,600 |
About Oragenics, Inc.
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
đ° Latest News
Oragenics previews targeted milestones for 2026
TipRanks âĸ 2026-02-10T13:46:12Z
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
TipRanks âĸ 2026-02-04T13:40:46Z
Oragenics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-07T21:26:27ZOragenics partners Receptor.AI for brain health candidate portfolio
Pharmaceutical Technology âĸ 2025-10-08T09:13:03Z
Oragenics: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-08T20:33:57ZOragenics partners with Southern Star Research for Phase IIa trial of ONP-002
Clinical Trials Arena âĸ 2025-08-01T10:55:51Z
Top Midday Decliners
MT Newswires âĸ 2025-07-01T18:27:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $785,930 | $29,828 | $30,591 | $15,103 |
| Total Expenses | $9,362,503 | $10,558,815 | $20,904,903 | $14,420,768 |
| Other Income Expense | $-13,193 | $-25,172 | $69,363 | $11,582 |
| Net Non Operating Interest Income Expense | $-603,701 | $16,069 | $179,803 | $120,797 |
| Interest Expense Non Operating | $785,930 | $29,828 | $30,591 | $15,103 |
| Operating Expense | $9,362,503 | $10,558,815 | $20,904,903 | $14,420,768 |
| General And Administrative Expense | $6,969,845 | $6,444,381 | $5,451,952 | $4,479,605 |
| Other Non Operating Income Expenses | - | - | $69,363 | $11,582 |
| Other Operating Expenses | - | - | $-37,653 | $-131,521 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Net Interest Income | $-603,701 | $16,069 | $179,803 | $120,797 |
| Interest Income | $182,229 | $45,897 | $210,394 | $135,900 |
| Normalized Income | $-9,829,473 | $-10,542,746 | $-20,655,737 | $-14,288,389 |
| Net Income From Continuing And Discontinued Operation | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Total Operating Income As Reported | $-9,362,503 | $-10,558,815 | $-20,904,903 | $-14,420,768 |
| Net Income Common Stockholders | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Net Income | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Net Income Including Noncontrolling Interests | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Net Income Continuous Operations | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Pretax Income | $-9,979,397 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Interest Income Non Operating | $182,229 | $45,897 | $210,394 | $135,900 |
| Operating Income | $-9,362,503 | $-10,558,815 | $-20,904,903 | $-14,420,768 |
| Per Share | ||||
| Diluted EPS | $-4.56 | $-47.88 | $-275.40 | $-213.30 |
| Basic EPS | $-4.56 | $-47.88 | $-275.40 | $-213.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $-179 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,180,274 | $-10,512,918 | $-20,597,755 | $-14,228,619 |
| Total Unusual Items | $-13,193 | $-25,172 | - | - |
| Total Unusual Items Excluding Goodwill | $-13,193 | $-25,172 | - | - |
| EBITDA (Bullshit earnings) | $-9,193,467 | $-10,538,090 | $-20,597,755 | $-14,228,619 |
| EBIT | $-9,193,467 | $-10,538,090 | $-20,625,146 | $-14,273,286 |
| Diluted Average Shares | $2,157,076 | $220,731 | $74,989 | $66,974 |
| Basic Average Shares | $2,157,076 | $220,731 | $74,989 | $66,974 |
| Diluted NI Availto Com Stockholders | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Tax Provision | $-136,910 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-13,193 | $-25,172 | - | - |
| Research And Development | $2,392,658 | $4,114,434 | $15,490,604 | $10,072,684 |
| Selling General And Administration | $6,969,845 | $6,444,381 | $5,451,952 | $4,479,605 |
| Other Gand A | $6,969,845 | $6,444,381 | $5,451,952 | $4,479,605 |
| Reconciled Depreciation | - | $0 | $27,391 | $44,667 |
| Other Taxes | - | - | - | $5,140 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,281,405 | $-211,885 | $3,168,154 | $13,009,302 |
| Total Assets | $10,067,764 | $1,472,510 | $4,966,335 | $14,758,025 |
| Total Non Current Assets | $0 | $0 | $1,100,561 | $468,502 |
| Current Assets | $10,067,764 | $1,472,510 | $3,865,774 | $14,289,523 |
| Other Current Assets | $1,614,956 | $607,670 | $382,273 | $2,862,738 |
| Receivables | $53,082 | $0 | - | $0 |
| Accrued Interest Receivable | $53,082 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $8,399,726 | $864,840 | $3,483,501 | $11,426,785 |
| Cash And Cash Equivalents | $4,399,726 | $864,840 | $3,483,501 | $11,426,785 |
| Non Current Prepaid Assets | - | $0 | $1,090,750 | $0 |
| Prepaid Assets | - | - | - | $2,862,738 |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $227,348 | $328,528 | $322,514 | $624,526 |
| Current Debt And Capital Lease Obligation | $227,348 | $328,528 | $322,514 | $472,087 |
| Current Debt | $227,348 | $328,528 | $312,703 | $267,640 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $152,439 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,786,359 | $1,684,395 | $1,798,181 | $1,748,723 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $152,439 |
| Current Liabilities | $1,786,359 | $1,684,395 | $1,798,181 | $1,596,284 |
| Current Notes Payable | $227,348 | $328,528 | $312,703 | $267,640 |
| Payables And Accrued Expenses | $1,559,011 | $1,355,867 | $1,467,686 | $1,090,652 |
| Payables | - | $1,144,634 | $1,244,947 | $246,690 |
| Accounts Payable | - | $1,144,634 | $1,244,947 | $246,690 |
| Equity | ||||
| Common Stock Equity | $8,281,405 | $-211,885 | $1,575,431 | $11,416,579 |
| Total Equity Gross Minority Interest | $8,281,405 | $-211,885 | $3,168,154 | $13,009,302 |
| Stockholders Equity | $8,281,405 | $-211,885 | $3,168,154 | $13,009,302 |
| Retained Earnings | $-226,628,659 | $-216,786,172 | $-206,218,254 | $-185,562,517 |
| Preferred Stock Equity | - | - | $1,592,723 | $1,592,723 |
| Other | ||||
| Ordinary Shares Number | $4,271,529 | $419,003 | $102,689 | $67,488 |
| Share Issued | $4,271,529 | $419,003 | $102,689 | $67,488 |
| Tangible Book Value | $8,281,405 | $-211,885 | $1,575,431 | $11,416,579 |
| Invested Capital | $8,508,753 | $116,643 | $1,888,134 | $11,684,219 |
| Working Capital | $8,281,405 | $-211,885 | $2,067,593 | $12,693,239 |
| Total Capitalization | $8,281,405 | $-211,885 | $3,168,154 | $13,009,302 |
| Additional Paid In Capital | $234,905,793 | $216,573,868 | $207,790,604 | $196,977,071 |
| Capital Stock | $4,271 | $419 | $1,595,804 | $1,594,748 |
| Common Stock | $4,271 | $419 | $3,081 | $2,025 |
| Preferred Stock | $0 | $0 | $1,592,723 | $1,592,723 |
| Other Short Term Investments | $4,000,000 | $0 | - | - |
| Capital Lease Obligations | - | $0 | $9,811 | $356,886 |
| Current Capital Lease Obligation | - | $0 | $9,811 | $204,447 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $8,399 | $7,981 | $33,545 |
| Current Accrued Expenses | - | $202,834 | $222,739 | $843,962 |
| Net PPE | - | $0 | $9,811 | $468,502 |
| Gross PPE | - | $0 | $9,811 | $1,831,741 |
| Treasury Shares Number | - | - | $0 | - |
| Long Term Capital Lease Obligation | - | - | $0 | $152,439 |
| Accumulated Depreciation | - | - | $0 | $-1,363,239 |
| Leases | - | - | $0 | $487,871 |
| Other Properties | - | - | $9,811 | $1,024,184 |
| Machinery Furniture Equipment | - | - | $0 | $319,686 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,246,387 | $-8,597,382 | $-8,290,880 | $-15,356,002 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,246,387 | $-8,597,382 | $-7,290,880 | $-15,228,483 |
| Cash Flow From Continuing Operating Activities | $-9,246,387 | $-8,597,382 | $-7,290,880 | $-15,228,483 |
| Operating Gains Losses | - | - | $29,956 | $-10,964 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-936,284 | $-115,519 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-936,284 | $-115,519 |
| Capital Expenditure | - | - | $-1,000,000 | $-127,519 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $17,653,890 | $6,671,830 | $849,926 | $69,289 |
| Financing Cash Flow | $16,781,273 | $5,978,721 | $283,880 | $-494,916 |
| Cash Flow From Continuing Financing Activities | $16,781,273 | $5,978,721 | $283,880 | $-494,916 |
| Net Preferred Stock Issuance | $15,019,700 | $0 | - | $0 |
| Preferred Stock Issuance | $15,019,700 | $0 | - | - |
| Net Common Stock Issuance | $2,634,190 | $6,671,830 | $849,926 | $69,289 |
| Common Stock Issuance | $2,634,190 | $6,671,830 | $849,926 | $69,289 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-3,328,528 | $-693,109 | $-566,046 | $-564,205 |
| Issuance Of Debt | $2,455,911 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $22,353 | $29,828 | $30,591 | $9,290 |
| End Cash Position | $8,399,726 | $864,840 | $3,483,501 | $11,426,785 |
| Beginning Cash Position | $864,840 | $3,483,501 | $11,426,785 | $27,265,703 |
| Changes In Cash | $7,534,886 | $-2,618,661 | $-7,943,284 | $-15,838,918 |
| Net Issuance Payments Of Debt | $-872,617 | $-693,109 | $-566,046 | $-564,205 |
| Net Short Term Debt Issuance | $-872,617 | $-693,109 | $-566,046 | $-564,205 |
| Short Term Debt Payments | $-3,328,528 | $-693,109 | $-566,046 | $-564,205 |
| Short Term Debt Issuance | $2,455,911 | $0 | $0 | $0 |
| Change In Working Capital | $-857,224 | $1,454,487 | $2,017,176 | $-1,716,000 |
| Change In Other Current Liabilities | $0 | $-9,811 | $-347,075 | - |
| Change In Other Current Assets | $0 | $9,811 | $337,629 | $0 |
| Change In Payables And Accrued Expense | $203,144 | $-119,800 | $25,798 | $176,625 |
| Change In Prepaid Assets | $-1,007,286 | $1,574,287 | $2,000,824 | $-1,899,612 |
| Change In Receivables | $-53,082 | $0 | $0 | $6,987 |
| Other Non Cash Items | $897,577 | - | $10,273,506 | - |
| Stock Based Compensation | $555,747 | $516,049 | $1,016,828 | $742,203 |
| Net Income From Continuing Operations | $-9,842,487 | $-10,567,918 | $-20,655,737 | $-14,288,389 |
| Net Intangibles Purchase And Sale | - | $0 | $-1,000,000 | $0 |
| Purchase Of Intangibles | - | $0 | $-1,000,000 | $0 |
| Net PPE Purchase And Sale | - | $0 | $63,716 | $-115,519 |
| Sale Of PPE | - | $0 | $63,716 | $12,000 |
| Depreciation Amortization Depletion | - | $0 | $27,391 | $44,667 |
| Depreciation And Amortization | - | $0 | $27,391 | $44,667 |
| Gain Loss On Sale Of PPE | - | $0 | $29,956 | $-10,964 |
| Purchase Of PPE | - | - | $0 | $-127,519 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Preferred Stock Payments | - | - | - | $0 |
Fetched: 2026-06-16